Published in final edited form as:

Org Lett. 2011 September 16; 13(18): 4786–4789. doi:10.1021/ol2017966.

Stereoselective Synthesis of F-Ring Saturated Estrone-Derived Inhibitors of Hedgehog Signaling Based on Cyclopamine

Zhihui Zhang, Valérie Baubet, Christian Ventocilla, Chaomei Xiang, Nadia Dahmane*, and Jeffrey D. Winkler*

Department of Chemistry, The University of Pennsylvania, Philadelphia, PA 19104 and The Wistar Institute, Molecular and Cellular Oncogenesis Program, Philadelphia, PA 19104

Abstract

Previous work in this laboratory established that the readily available F-ring aromatic analog of cyclopamine is a highly potent inhibitor of Hedgehog signaling. The synthesis and biological evaluation of two F-ring saturated analogs that are more potent than the F-ring aromatic structure are reported.

Some time ago it was found that ingestion of the California corn lily, *veratrum californicum*, by pregnant sheep could induce cyclopia and other profound developmental defects in the offspring. Keeler and coworkers established that the active constituent in the plant is the alkaloid cyclopamine **1** (Figure 1),ⁱ and it was later found that cyclopamine mediates this effect by interfering with Sonic Hedgehog (SHH) signaling,ⁱⁱ specifically via the inhibition of the transmembrane protein Smoothened (SMO).ⁱⁱⁱ SHH signaling is active in the majority of sporadic basal cell carcinomas^{iv} and also in brain tumors, including medulloblastomas and gliomas.^v This signaling pathway has also been linked to melanoma,^{vi} lung adenocarcinoma,^{vii} as well as prostate,^{viii} small cell lung,^{ix} and pancreatic cancer.^x As a result, the development of inhibitors of the SHH cellular signaling pathway has emerged as an important goal in medicinal chemistry.^{xi} The most common strategy in the pharmaceutical industry has involved the screening of libraries of diverse chemical structures in the hope of discovering drug-like structures that will interfere with SHH signaling. The most noteworthy success to date using this approach is GDC-0449 **2** (Figure 1), a compound that is currently in Phase II clinical trials.^{xii}

Using a conceptually different approach, we have recently shown that designed, structurally simplified, cyclopamine-like structures such as the estrone-derived analog **3** (Figure 1) are potent inhibitors of Hedgehog signaling.^{xiii} These analogs offer two important advantages over cyclopamine **1**: 1) they do not contain the allylic ether present in **1** that confers metabolic, i.e., acid, instability; and 2) they are easily prepared (four chemical steps) from commercially available steroids, i.e., estrone.

*winkler@sas.upenn.edu; ndahmane@wistar.org.

Supporting Information Available Full experimental details, characterization data and NMR spectra of all compounds, and crystallographic data (CIF). This material is available free of charge via the Internet at <http://pubs.acs.org>.

There are several important structural differences between the estrone-derived lead structure **3** and cyclopamine **1**, notably the presence of the aromatic A and F rings in **3** that are not present in **1** (Figure 1). We report herein the design and synthesis of F-ring saturated analogs of **3** that are related to **4**, that contains the same relative stereochemistry at C-22 and C-23 as cyclopamine **1**, and that the SHH signaling inhibitory activity of these new analogs is greater than that of cyclopamine **1** in medulloblastoma cell viability assays.

While the direct reduction of the pyridine ring in **3** would appear to be the most direct approach to the synthesis of F-ring saturated analogs, i.e., **4**, we have found the pyridine ring in **3** resistant to direct reduction without extensive decomposition.

Instead, we have developed an alternative approach to the synthesis of F-ring saturated analogs, that leads, *inter alia*, to the synthesis of novel structural analogs lacking the E-ring tetrahydrofuran present in both **1** and in **3**. These new compounds are highly potent inhibitors of SHH signaling, suggesting that the tetrahydrofuran E ring of cyclopamine is not required for biological function.

We envisioned that the EF heterocyclic moiety of the target structure **4** could be prepared via nitrenium ion mediated bicyclization of **5** (Figure 2). Elegant studies by Wardrop^{xiv} have suggested that such an approach should be feasible. We have initiated a more incremental approach to the synthesis of the EF heterobicyclic ring system, via iodoetherification of **7** to give **6**, which on treatment with ammonia would generate the requisite EF heterobicyclic ring system. The synthesis and reaction of the key iodoetherification substrate **10** is outlined in Scheme 1.

Reaction of the known epoxide **8**^{xv} (Scheme 1) with the anion formed from the *t*-butyldiphenylsilyl ether of 4-pentynol and removal of the silyl protecting group with TBAF provided alkynol **9**. Reduction of **9** with LiAlH₄ stereoselectively provided the (*E*)-alkenol that was reacted with TsCl to generate **10**. In analogy to the work of Knight^{xvi} and Lipshutz^{xvii} on the iodocyclization of homoallylic alcohols, exposure of **10** to iodine and sodium bicarbonate efficiently led to the anticipated *trans*-β-iodotetrahydrofuran **11** as a single diastereomer.^{xviii}

The stereochemical outcome of the reaction is consistent with the model proposed by Knight, in which conformation A, which leads to the formation of the observed product **11**, is favored over conformation B, which would lead to the formation of the diastereomeric *trans*-disubstituted tetrahydrofuran **13** (only the hydrindane moiety of the estrone framework is shown; Figure 3).

Reaction of **11** with liquid ammonia afforded a piperidine product via displacement of both the iodide and tosylate moieties present in **10**, followed by reductive debenzoylation to generate **12** (in nine chemical steps and 23% overall yield from estrone), the structure of which was confirmed by X-ray crystallographic analysis of the derived para-bromobenzamide. We note that **12** is epimeric with the target structure **4** (Figure 1) at C-22, i.e., *cis*- instead of *trans*-EF ring fusion.

Although the work of Knight had demonstrated that the iodoetherification of *Z*-homoallylic alcohols was slower than that of the *E*-alkene substrates, we envisioned that the *trans* EF ring fusion stereochemistry found in cyclopamine and in **4** could result from analogous reaction of **14**, the *Z*-alkene corresponding to **10**, the synthesis of which is outlined in Scheme 2.

In the event, Lindlar reduction of **9** (Scheme 1) afforded **14**, which on exposure to iodine-mediated cyclization conditions afforded not the anticipated tetrahydrofuran product

analogous to **11** (Scheme 1) but instead the oxetane **15** in 64% yield. Reaction of bis-electrophile **15** with ammonia afforded the oxetane-pyrrolidine **16** in 55% overall yield after O-debenzylation. The stereochemistry of **16** was unequivocally established by X-ray crystallographic analysis of the derived 3,5-dinitrobenzamide, confirming that the cyclization occurred with the analogous orientation of the *Z*-alkene (A' in Scheme 2) as shown in A for the *E*-alkene cyclization substrate **10** (Scheme 1). However, instead of the anticipated tetrahydrofuran product (the result of 5-endo cyclization), based on the work of Knight, we observed the exclusive formation of the oxetane product **15**, the result of 4-exo cyclization of **14**. The basis for this surprising regiochemical outcome is currently under study in our laboratory.

Preliminary biological evaluation of **12** and **16** reveals that both are highly potent inhibitors of Hedgehog signaling, comparable to cyclopamine **1** in potency.^{xxix} We first tested **12** and **16** for their activity on the SHH signaling pathway by using the SHH-Light2 cells: this cell line is a 3T3 clone that stably expresses a GLI-dependent reporter.^{xx} Treatment of these cells with recombinant SHH activates GLI-dependent firefly luciferase expression and this SHH-induced activation is inhibited when cells are also treated with cyclopamine **1**. In this assay, SHH-light2 cells were treated with SHH (600 ng/ml, R&D) alone or in combination with cyclopamine **1**, **12** or **16** (all at 5 μ M). As illustrated in Figure 4, **12** and **16** both lead to a strong inhibition of SHH signaling activity comparable to that of cyclopamine.

Granule neuron precursors (GNPs) represent a physiological system for the testing of SHH inhibition, as SHH is a potent mitogen for postnatal mouse cerebellar GNPs,^{xxi} and cyclopamine **1** is known to block their proliferation.^{xxii} In the event, GNPs were purified from postnatal day 5 (P5) mouse cerebella and treated with either SHH alone or in combination with **1**, **12** or **16** (all at 5 μ M). BrdU was added to the media 6 hours before fixation. Percentage of brdU positive cells were determined by counting with a fluorescence microscope using a 20X objective (Axioskop, Zeiss). At least five independent fields for each culture condition were counted. The analysis was performed on three independent experiments. As illustrated in Figure 5, GNP proliferation in response to SHH signalling activation is blocked with **1** as well as with compounds **12** and **16**.

Abnormal activation of the SHH signaling pathway has been linked to various cancers including medulloblastoma, a malignancy of the cerebellum with the highest incidence of all human pediatric malignant brain tumors.^{xxiii} A subset of these tumors is thought to arise from deregulation of granule neuron precursor (GNP) development in the cerebellum and require SHH signaling for their growth. We thus tested whether compounds **12** and **16** were also efficient in reducing the viability of medulloblastoma cells using human medulloblastoma DAOY cells. DAOY cells were treated for 72 hours with either cyclopamine **1**, **12** or **16** before cell survival was assayed with a colorimetric MTT assay, in which absorbance at 570 nm is directly proportional to the number of living cells. As illustrated in Figure 6, there is a significant decrease in cell survival when the cells are treated with either cyclopamine **1**, **12**, or **16**, and that both **12** and **16** are more active in reducing DAOY cell viability than **1**.

The significance of the structures of **12** and **16** for observed potency in these diverse biological systems is underscored by the recent disclosure of the synthesis and biological activity of desmethylveramiline **17**, which represents a des-E analog of cyclopamine **1**, by Mann and coworkers (Figure 7).^{xxiv} They report that **17** is ca. 50% less potent than **1** in the same SHH-light2 assay described in Figure 4, in which **16** is equipotent with **1**, suggesting that the rigidity imparted by the oxetane ring is important to the observed potency of **16**.

We have developed structurally novel analogs **12** and **16** of cyclopamine **1** that exhibit enhanced potency relative to **1** in both GNP proliferation and MAOY medulloblastoma cellular assays. Further studies on stereoisomeric analogs of **12** and **16** and related structures are currently underway in our laboratory and our results will be reported in due course.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We gratefully acknowledge the NIH (CA-134983) for their generous support of this work and the NSF for an X-ray diffractometer (CHE-0840438). We would like to thank Dr. Patrick Carroll for X-ray structure determinations, Drs. George Furst and Jun Gu for their assistance with NMR spectroscopy, and Dr. Rongbiao Tong (Department of Chemistry, University of Pennsylvania) for helpful discussions.

References

- i. a) Binns W, James L, Keeler R, Balls L. *Cancer Res.* 1968; 28:2323–6. [PubMed: 5749423] b) Keeler R, Binns W. *Can J Biochem.* 1966; 44:829–38. [PubMed: 5950658]
- ii. Cooper M, Porter J, Young K, Beachy P. *Science.* 1998; 280:1603–7. [PubMed: 9616123] b) Incardona J, Gaffield W, Kapur R, Roelink H. *Development.* 1998; 125:3553–62. [PubMed: 9716521]
- iii. Chen J, Taipale J, Cooper M, Beachy P. *Genes Dev.* 2002; 16:27:43–8.
- iv. Dahmane N, Lee J, Robbins P, Heller P, Ruiz A, Altaba I. *Nature.* 1997; 389:876–81. [PubMed: 9349822]
- v. a) Berman D, Karhadkar S, Hallahan A, Pritchard J, Eberhart C, Watkins D, Chen J, Taipale J, Olson J, Beachy P. *Science.* 2002; 297:1559–61. [PubMed: 12202832] b) Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruiz i Altaba A. *Curr. Biol.* 2007; 17:165–72. [PubMed: 17196391] c) Dahmane N, Sanchez P, Gitton Y, Palma V, Sun T, Beyna M, Weiner H, Ruiz i Altaba A. *Development.* 2001; 128:5201–12. [PubMed: 11748155]
- vi. Stecca B, Mas C, Clement V, Zbinden M, Correa R, Piguet V, Beermann F, Ruiz A. *Proc. Natl. Acad. Sci. U S A.* 2007; 104:5895–900. [PubMed: 17392427]
- vii. Yuan Z, Goetz J, Singh S, Oden S, Petty W, Black C, Memoli V, Dmitrovsky E, Robbins D. *Oncogene.* 2007; 26:1046–55. [PubMed: 16909105]
- viii. a) Karhadkar S, Bova G, Abdallah N, Dhara S, Gardner D, Maitra A, Isaacs J, Berman D, Beachy P. *Nature.* 2004; 431:707–12. [PubMed: 15361885] b) Sanchez P, Hernandez A, Stecca B, Kahler A, DeGueme A, Barrett A, Beyna M, Datta M, Datta S, Ruiz A. *Proc Natl Acad Sci U S A.* 2004; 101:12561–6. [PubMed: 15314219] c) Sheng T, Li C, Zhang X, Chi S, He N, Chen K, McCormick F, Gatalica Z, Xie J. *Mol Cancer.* 2004; 3:29. [PubMed: 15482598]
- ix. Watkins D, Berman D, Burkholder S, Wang B, Beachy P, Baylin S. *Nature.* 2003; 422:313–7. [PubMed: 12629553]
- x. Berman D, Karhadkar S, Maitra A, Montes D, Gerstenblith M, Briggs K, Parker A, Shimada Y, Eshleman J, Watkins D, Beachy P. *Nature.* 2003; 425:846–51. [PubMed: 14520411]
- xi. For recent SAR on cyclopamine-derived structures, see a) Heretsch P, Buttner A, Tzagkaroulaki L, Zahn S, Kirchner B, Giannis A. *Chem. Commun.* 2011; 47:7362–7364. b) Tremblay M, Nevalainen M, Nair S, Porter J, Castro A, Behnke M, Yu L, Hagel M, White K, Faia K, Grenier L, Campbell M, Cushing J, Woodward C, Hoyt J, Foley M, Read M, Sydor J, Tong J, Palombella V, McGovern K, Adams J. *J. Med. Chem.* 2008; 51:6646–6649. [PubMed: 18842035] For a general discussion, see Dolgin E. *Nature Medicine.* 2011; 17:523.
- xii. Sheridan C. *Nature Biotech.* 2009; 27:968–969.
- xiii. Winkler J, Isaacs A, Holderbaum L, Tatard V, Dahmane N. *Org Lett.* 2009; 11:2824–7. [PubMed: 19552464]
- xiv. Wardrop D, Bowen E, Forslund R, Sussman A, Weerasekera S. *J. Am. Chem. Soc.* 2010; 132:1188–1189. [PubMed: 19788297]

- xv. Cook C, Corley R, Wall M. J. Org. Chem. 1968; 33:2789–93. [PubMed: 5742839]
- xvi. Bedford S, Bell K, Bennett F, Hayes C, Knight D, Shaw D. J. Chem. Soc., Perkin Trans. 1. 1999; 15:2143–2153.
- xvii. Lipshutz B, Barton J. J. Am. Chem. Soc. 1992; 114:1084–6.
- xviii. All compounds were characterized by full spectroscopic (NMR, IR, high resolution MS) data. Yields refer to spectroscopically and chromatographically homogeneous (>95%) materials.
- xix. Control experiments comparing the SHH inhibitory activity of estrone with **3** suggest that the activity of these estrone-derived analogs is not an estrogenic effect (Ref. 13).
- xx. Taipale J, Chen J, Cooper M, Wang B, Mann R, Milenkovic L, Scott M, Beachy P. Nature. 2000; 406:1005–1009. [PubMed: 10984056]
- xxi. Dahmane N, Ruiz i Altaba A. Development. 1999; 26:3089–3100. [PubMed: 10375501]
- xxii. Fernandez C, Tatard V, Bertrand N, Dahmane N. Dev Neurosci. 2010; 32:59–70. [PubMed: 20389077]
- xxiii. Ellison D. Neuropathol. 2010; 120:305–316.
- xxiv. Guerlet G, Spangenberg T, Mann A, Faure H, Ruat M. Bioorg. Med. Chem. Lett. 2011; 21:2608–3612.

Figure 1.
Structures of Cyclopamine **1**, GDC-0449 **2**, Estrone Analog **3** and Saturated Analog **4**

Figure 2.
Complementary Approaches to the Synthesis of the F-Ring Saturated Analog **4**

Figure 3.
Rationale for the Observed Formation of **11** and not **13** in the Cyclization of *E*-Alkene **10**

Figure 4. **12** and **16** are potent inhibitors of the SHH-induced GLI-luciferase activity in SHH-Light2 cells. The asterisk indicates p-value $p < 0.001$.

Figure 5.
12 and **16** block SHH-induced granule neuron precursor (GNP) proliferation. Statistical analysis was performed with the Student t test. The asterisk indicates the following p-value: * $p < 0.05$, ** $p < 0.01$.

Figure 6. Effect of **12** and **16** on cell survival of human medulloblastoma DAOY cells. The asterisk indicates p-value $p < 0.05$.

Figure 7.
Desmethylveramiline

Scheme 1.
Synthesis and Cyclization of *E*-Alkene Substrate **10** to give **12**

Scheme 2.
Synthesis and Cyclization of Z-Alkene Substrate **14** to Give Pyrrolidino-Oxetane **16**